ClinicalTrials.gg
CompletedNCT03957746Updated Oct 5, 2021

Set Volume of Optimal Resistance Exercise to Generate Hypotension

An interventional study of Resistance training in Hypertension, Post-Exercise Hypotension and Resistance Training, sponsored by University of Valencia. Completed at 1 site in Spain. Open to participants aged 55 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-10-05.

Sponsored by University of Valencia · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
55 Years to 70 Years
Sex
All
01

Study summary

This study evaluates the volume of optimal resistance exercise to generate postexercise hypotension after performing a single exercise in hypertensive elderly subjects. 20 subjects will perform 1 control session and 3 resistance training sessions with different volume: 3, 6 and 9 sets

02

Conditions studied

  • Hypertension
  • Post-Exercise Hypotension
  • Resistance Training
03

In context

Hypertension

6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.

This study's enrollment of 19 is below the median of 100 across 4,575 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

University of Valencia is the lead sponsor of 357 studies on the registry; 75 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hypertensive subjects treated with antihypertensive medication
  • Controlled blood pressure
  • Age between 55 and 70 years old
  • Sedentary (less than 150 minutes per week of moderate physical activity and/or 75 minutes per week of vigorous physical activity)
  • Non-smokers
  • Non-alcoholics

Exclusion criteria

Exclusion Criteria:

  • Any kidney, lung, neurological or psychiatric disease
  • Unable to perform exercises
  • Participation in other physical activity programs during the study or in the previous 3 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    3 sets of resistance exercise

    Other: Resistance training

  • Experimental
    6 sets of resistance exercise

    Other: Resistance training

  • Experimental
    9 sets of resistance exercise

    Other: Resistance training

  • No intervention
    Rest

Interventions

  • OtherResistance training

    3, 6 or 9 sets of biceps curl with elastic bands at 20 repetition-maximum (RM)

06

What researchers measure

Primary outcomes

  1. Blood pressure

    Time frame: Baseline

  2. Blood pressure

    Time frame: Immediately after the end of resistance training session

  3. Blood pressure

    Time frame: 30 minutes after the end of resistance training session

  4. Blood pressure

    Time frame: 60 minutes after the end of resistance training session

  5. Blood pressure

    Time frame: 4 hours after the end of resistance training session

  6. Blood pressure

    Time frame: 5 hours after the end of resistance training session

  7. Blood pressure

    Time frame: 6 hours after the end of resistance training session

Secondary outcomes

  1. Heart rate

    Time frame: Baseline

  2. Heart rate

    Time frame: Immediately after the end of resistance training session

  3. Heart rate

    Time frame: 30 minutes after the end of resistance training session

  4. Heart rate

    Time frame: 60 minutes after the end of resistance training session

  5. Heart rate

    Time frame: 4 hours after the end of resistance training session

  6. Heart rate

    Time frame: 5 hours after the end of resistance training session

  7. Heart rate

    Time frame: 6 hours after the end of resistance training session

07

Study locations

1 site
  • Primary Health-Care Center
    Rocafort, Valencia 46111, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03957746
Responsible party
José Casaña Granell (Director, PhD, University of Valencia) — Principal investigator
First posted
May 21, 2019
Start date
May 13, 2020
Primary completion
Oct 1, 2020
Completion
Oct 3, 2021
Last update
Oct 5, 2021

Study contacts

Jose Casaña
principal investigator · University of Valencia
Joaquín Calatayud
study chair · University of Valencia
Alba Cuerda
study chair · University of Valencia

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion